ArticleALTEX2026
What does "success" look like in compliance check decisions by the European Chemicals Agency? The curious cases of accepted read-across adaptations.
Article in ALTEX, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- New approach methodologies in food safety: A survey and commentary on industry adoption, barriers, and the path to regulatory adoption.Regulatory toxicology and pharmacology : RTP · 2026Article
- NGRA in Cosmetic Safety: Moving From the Frameworks and Case Studies to Wide Adoption.Current opinion in toxicology · 2026Article
- Human vs. cells vs. machine: A comparative analysis of toxicological points of departure derived from quantitative read-across (qRAx), in vitro data, and In silico predictions.Regulatory toxicology and pharmacology : RTP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Under the European Union’s REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) regulation, the European Chemicals Agency (ECHA) is required to assess the compliance of safety data submitted by chemical registrants. ECHA must check a proportion of registration dossiers for compliance. From 2010 to 2023, 4,854 compliance checks (CCHs) were conducted. When dossiers lack required studies or use inappropriate adaptations, ECHA issues decisions that are publicly available. As of April 2, 2024, 2,311 such decisions had been published. This study systematically analyzed these published CCH decisions, focusing on ECHA’s findings of non-compliant REACH registrations and the use of adaptations to standard information requirements. We found that over 70% of published CCH decisions included at least one adaptation, with “read-across” being the most common (48%). Among these, 83 documents contained read-across adaptations with justifications that ECHA deemed plausible. To understand what made these read-across hypotheses acceptable, we evaluated them using 17 assessment elements that capture specific arguments registrants proposed to justify the adaptation. Elements of “acceptable” read-across hypotheses included strong evidence of (i) toxicokinetic similarity between the registered substance and its analogues, and (ii) toxicodynamic similarity, supported by bridging studies. Additional support from in vitro studies and QSAR predictions further strengthened the accepted read-across hypotheses. Overall, this analysis provides insights into what constitutes a successful read-across under REACH data requirements. By identifying and evaluating accepted cases or read-across adaptations, we highlight best practices for establishing scientifically robust justifications for chemical similarity that can meet ECHA’s high regulatory standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.